Examine how branded and biosimilar companies build, litigate, and defend formulation and delivery patents as core composition claims expire and these assets become the last line of exclusivity.
Discuss how assignor estoppel shapes litigation strategy for biotech companies facing founder-originated patents, and discover the most effective defence, settlement, and risk management strategies.
Explore how evergreening strategies and recent EU regulatory reforms are shaping competition, access, and patent lifecycle management across the pharmaceutical landscape.
How the Canadian and American court system deals with medical treatment and dosage cases, including Janssen Inc. v. Pharmascience Inc. (Supreme Court of Canada).
How enforcement, settlement posture, and leverage change once the first generic or biosimilar has already entered the market.
Discuss disputes where manufacturing processes, scale, or technical constraints ultimately dictated infringement and validity outcomes.
A focused look at litigating patents in India where manufacturing scale, pricing pressure, and public-interest arguments materially affect outcomes.
A practical discussion on how in-house teams decide not to sue despite apparent infringement. Focused on risk, cost, precedent, and internal decision-making rather than legal theory.
How patent disputes reveal weaknesses in claim drafting and specification support, and how litigation outcomes are reshaping prosecution strategy for device portfolios.
Olivier Marchand is Regenerative Agriculture Manager at Nestlé, with over 20 years of experience driving sustainability, quality, and responsible practices across value chains.
With a strong background in purchasing, quality assurance, and agriculture, he has worked across Europe, Africa, Latin America, and Asia, bringing a global and cross-cultural perspective. He focuses on strengthening traceability, sustainability, and trust, helping meet growing consumer expectations around product origin, production methods, and social responsibility.